Latest Aura Biosciences News & Updates

See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aura Biosciences

Clinical-stage biotechnology company developing targeted therapies for ocular cancers

aurabiosciences.com

Headquarters: Boston, United States
Founded year: 2009
Company type: Public company
Number of employees: 120–200
Industry: Biotechnology & Medical Research

Last updated September 20

Latest news about Aura Biosciences

In short: Aura Biosciences fully enrolled its Phase 3 CoMpass trial, raised capital, and appointed a new CEO.

Company announcements

August 11 Aura Biosciences

Aura Biosciences reports Q2 2026 financial results and strategic update

Phase 3 CoMpass trial fully enrolled with 108 patients; company restructures, appoints new executives, and extends cash runway into 2029.

June 1 Aura Biosciences

Aura Biosciences completes enrollment in Phase 3 CoMpass trial

Topline data expected in second half of 2027. Bel-sar may become first approved vision-preserving therapy for early choroidal melanoma.

May 11 Aura Biosciences

Aura Biosciences reports Q1 2026 financial results and business highlights

Phase 3 CoMpass trial nearing enrollment completion; topline data expected in 2H 2027. New CEO appointed, and $299M equity financing strengthened cash position.

May 5 Aura Biosciences

Aura Biosciences announces closing of $299 million public offering

The offering includes full exercise of underwriters' option, selling 46 million shares and pre-funded warrants at $6.00 per share.

Media coverage

September 20 MarketScreener

Aura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry Index

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Companyâ€s...

August 19 Yahoo

Thousands of Americans live with this rare condition—New drug may give hope

The experimental drug could become the first approved treatment for Guillain-Barré syndrome, a...

August 12 Seeking Alpha

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

This is the first time I have covered Aura Biosciences, Inc. (AURA) for Seeking Alpha—the Boston, Massachusetts-based pharma completed its Initial Public Offering ("IPO") in...

August 11 FierceBiotech

Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer

Aura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as the Boston biotech narrows its...

Never miss news about Aura Biosciences

Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aura Biosciences competitors & trending companies

Browse news for competitors to Aura Biosciences and other trending companies.